A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Dose Escalation: To evaluate the safety and tolerability of peposertib in combination with low-dose liposomal doxorubicin as evaluated by the dose-limiting toxicity (DLT) rate at each tested dose level. Dose Escalation: To determine the recommended ph
Why this Research Matters
This is a Phase 1, open lable, study of Peposertib (M3814) and low-dose Liposomal Doxorubicin in patients with Metastatic leiomyosarcoma and other soft tissue sarcomas.
Who can Participate
-Patients must have histologically confirmed sarcoma that is metastatic or unresectable and for which there is no known curative treatment. -Dose escalation cohort: Patients must have histologic diagnosis of leiomyosarcoma (LMS) or selected soft tissue Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov
Study ID
Protocol Number: 25-0217
More information available at ClinicalTrials.gov: NCT05711615
Meet the Team
Principal Investigator